NCT05386511已完成不适用
An Observational, Real-world Study Study of UTD1 in Chinese Advanced Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients aged over 18 years old.
- •Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- •Plan to receive or has received UTD1 monotherapy or UTD1 based therapy
- •Available medical history.
排除标准
- •1.Incomplete medical history.
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Adverse events(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.Breast NeoplasmsNCT00078000Pfizer64
招募中
2 期
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerAdvanced Breast CancerNCT04965766Gustave Roussy, Cancer Campus, Grand Paris139
已完成
1 期
Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsBreast CancerNCT02628132King Faisal Specialist Hospital & Research Center22
已完成
不适用
Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine TherapyBreast Cancer Stage IVNCT04133207Hellenic Cooperative Oncology Group340
撤回
1 期
Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)HER2 Negative Breast Cancer Not Immediately OperatedNCT05664893Centre Antoine Lacassagne85